Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Correction and Hepatic Differentiation of Hemophilia B-specific Human Induced Pluripotent Stem Cells.

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih - 27 Sept 2017

He Qiong, Wang Hui-Hui, Cheng Tao, Yuan Wei-Ping, Ma Yu-Po, Jiang Yong-Ping, Ren Zhi-Hua

Abstract excerpt

Objective To genetically correct a disease-causing point mutation in human induced pluripotent stem cells (iPSCs) derived from a hemophilia B patient. Methods First, the disease-causing mutation was detected by sequencing the encoding area of human coagulation factor IX (F IX) gene. Genomic DNA was extracted from the iPSCs, and the primers were designed to amplify the eight exons of F IX. Next, the point mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Differentiation
Share to Factor IX

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Hemophilia B

Share to Induced Pluripotent Stem Cells

Share to Mutation

Source

Identifiers

PMID: 28956740
DOI: 10.24920/J1001-9294.2017.032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Correction and Hepatic Differentiation of Hemophilia B-specific Human Induced Pluripotent Stem Cells.PMID 28956740Read ↗

Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 systemSemantic proximity Read ↗

CRISPR-Mediated In Situ Introduction or Integration of F9-Padua in Human iPSCs for Gene Therapy of Hemophilia B.Semantic proximity Read ↗

ssODN-Mediated In-Frame Deletion with CRISPR/Cas9 Restores FVIII Function in Hemophilia A-Patient-Derived iPSCs and ECsSemantic proximity Read ↗

CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.Semantic proximity Read ↗

Restoration of FVIII Function and Phenotypic Rescue in Hemophilia A Mice by Transplantation of MSCs Derived From F8-Modified iPSCsSemantic proximity Read ↗

Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology.Semantic proximity Read ↗

Amelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integrationSemantic proximity Read ↗

Generation of a human induced pluripotent stem cell line, YCMi002-A, from a Factor VII deficiency patient carrying F7 mutations.Semantic proximity Read ↗

In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCsSemantic proximity Read ↗

Generation of iPSC line from urine cells of hemophilia A with F8 (p. R814X) mutation.Semantic proximity Read ↗

Generation of induced pluripotent stem cell, BCHSCTi001-A, derived from a Hemophilia A patient with F8 (p. R391C) mutation.Semantic proximity Read ↗

CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.